Report
Eric Le Berrigaud

ZEALAND: The right CEO, at the right time, to convey new messages and prepare for the next phase | BUY | DKK180 vs. DKK143 (+31%)

ZEALAND - BUY | DKK180 vs. DKK143 (+31%)
The right CEO, at the right time, to convey new messages and prepare for the next phase

First very positive impression from first meeting with new CEO
Glepaglutide should do better than Gattex
Dasiglucagon: a multi-dimensional discussion to conduct
Underlying
Zealand Pharma A/S

Zealand Pharma is a biotechnology company. Co. is engaged in the discovery development and commercialization of peptide-based medicines. Co.'s pipeline comprises two implementation areas: Cardio-metabolic diseases and Other indications. The Cardio-metabolic diseases area includes medicines for diabetes and obesity treatment, such as Lyxumia (Lixisenatide), Lyxumia/Lantus, ZP2929 and Danegaptide. The Other indications area are ZP1848, Elsiglutide and ZP1480 (ABT-719) drugs for inflammatory bowel disease, chemotherapy-induced diarrhea and acute kidney injury treatment.

Provider
Bryan Garnier
Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

Analysts
Eric Le Berrigaud

Other Reports on these Companies
Aurelien Sivignon ...
  • Fehmi Ben Naamane
  • Jean Sassus
  • Jean-François Granjon
  • Matthias Desmarais
  • Oussema Denguir
  • Pierre Corby
  • Steven Gould
Other Reports from Bryan Garnier
Other Reports from these Analysts

ResearchPool Subscriptions

Get the most out of your insights

Get in touch